Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1Dermatologic 1CNS 1Breast 1

Conditions

Neoplasm Metastasis 4Lung Neoplasms 4Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Cholangiocarcinoma 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Tertiary Lymphoid Structures 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Nasopharyngeal Carcinoma 1Microsatellite Instability 1Mesothelioma, Malignant 1Mesothelioma 1Melanoma 1Hematologic Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Squamous Cell 1Camurati-Engelmann Syndrome 1Brain Neoplasms 1Biliary Tract Neoplasms 1Anatomic Stage II Breast Cancer AJCC v8 1

Interventions

Nivolumab 146Ipilimumab 137pembrolizumab 122Cyclophosphamide 78Interleukin-2 69aldesleukin 63Temozolomide 46trametinib 37Radiosurgery 37Vemurafenib 36fludarabine 34Biopsy 34dabrafenib 33Radiotherapy 33Blood Specimen Collection 31fludarabine phosphate 30sargramostim 27Bevacizumab 27Introns 23Dacarbazine 22Magnetic Resonance Spectroscopy 21CTLA-4 Antigen 20encorafenib 19cobimetinib 19binimetinib 19Specimen Handling 19Paclitaxel 19Granulocyte-Macrophage Colony-Stimulating Factor 19Cisplatin 17incomplete Freund's adjuvant 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Melanoma × bintrafusp alfa protein, human × Clear all
NCT04789668 2026-03-18

Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases

M.D. Anderson Cancer Center

Phase 1/2 Terminated
8 enrolled 13 charts
BreastCNSDermatologicOther hematologic neoplasmThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Hematologic Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡